Literature DB >> 11243877

Protease inhibitors divert amyloid precursor protein to the secretory pathway.

J F Hare1.   

Abstract

Addition of cysteine protease inhibitors to cells expressing amyloid precursor protein (APP) resulted in a >2-fold increase in appearance of the secreted extracellular domain of APP in the media. This was accounted for by increased flux of APP into the secretory pathway since protease inhibitors also caused a twofold increase in newly translated, incompletely glycosylated APP detected by pulse-labeling. These results show that a portion of newly translated APP molecules are normally rapidly degraded by cysteine protease(s) but can enter the secretory pathway when degradation is inhibited. Newly translated APP molecules are thus still competent for posttranslational processing in distal cellular compartments. Their degradation thus may not result from misfolding but merely susceptibility to an endoplasmic reticulum localized cysteine protease. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11243877     DOI: 10.1006/bbrc.2001.4507

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  3 in total

1.  Inhibition of acyl-coenzyme A: cholesterol acyl transferase modulates amyloid precursor protein trafficking in the early secretory pathway.

Authors:  Henri J Huttunen; Camilla Peach; Raja Bhattacharyya; Cory Barren; Warren Pettingell; Birgit Hutter-Paier; Manfred Windisch; Oksana Berezovska; Dora M Kovacs
Journal:  FASEB J       Date:  2009-07-22       Impact factor: 5.191

2.  A novel mechanism for the regulation of amyloid precursor protein metabolism.

Authors:  Qi Chen; Hideo Kimura; David Schubert
Journal:  J Cell Biol       Date:  2002-07-01       Impact factor: 10.539

3.  Amyloid Precursor Proteins Are Dynamically Trafficked and Processed during Neuronal Development.

Authors:  Jenna M Ramaker; Robert S Cargill; Tracy L Swanson; Hanil Quirindongo; Marlène Cassar; Doris Kretzschmar; Philip F Copenhaver
Journal:  Front Mol Neurosci       Date:  2016-11-25       Impact factor: 5.639

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.